- Home
- ULS vs EXAS Comparison
ULS vs EXAS Comparison
Compare ULS & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ULS
- EXAS
- Stock Information
- Founded
- ULS 1894
- EXAS 1995
- Country
- ULS United States
- EXAS United States
- Employees
- ULS N/A
- EXAS N/A
- Industry
- ULS
- EXAS Medical Specialities
- Sector
- ULS
- EXAS Health Care
- Exchange
- ULS Nasdaq
- EXAS Nasdaq
- Market Cap
- ULS 9.8B
- EXAS 10.5B
- IPO Year
- ULS 2024
- EXAS N/A
- Fundamental
- Price
- ULS $51.93
- EXAS $51.74
- Analyst Decision
- ULS Buy
- EXAS Strong Buy
- Analyst Count
- ULS 11
- EXAS 16
- Target Price
- ULS $49.00
- EXAS $72.80
- AVG Volume (30 Days)
- ULS 702.9K
- EXAS 2.2M
- Earning Date
- ULS 01-24-2025
- EXAS 02-19-2025
- Dividend Yield
- ULS 0.72%
- EXAS N/A
- EPS Growth
- ULS 8.21
- EXAS N/A
- EPS
- ULS 1.51
- EXAS N/A
- Revenue
- ULS $2,815,000,000.00
- EXAS $2,692,328,000.00
- Revenue This Year
- ULS $7.80
- EXAS $11.81
- Revenue Next Year
- ULS $5.99
- EXAS $11.52
- P/E Ratio
- ULS $34.28
- EXAS N/A
- Revenue Growth
- ULS 7.32
- EXAS 11.91
- 52 Week Low
- ULS $33.15
- EXAS $40.62
- 52 Week High
- ULS $59.23
- EXAS $79.62
- Technical
- Relative Strength Index (RSI)
- ULS N/A
- EXAS 35.28
- Support Level
- ULS N/A
- EXAS $49.79
- Resistance Level
- ULS N/A
- EXAS $60.88
- Average True Range (ATR)
- ULS 0.00
- EXAS 2.67
- MACD
- ULS 0.00
- EXAS -0.59
- Stochastic Oscillator
- ULS 0.00
- EXAS 17.58
About ULS UL Solutions Inc.
UL Solutions is a global leader specializing in a broad range of product testing, inspection, and certification services. UL Solutions is the for-profit branch out of three organizations under the UL Enterprise. TIC operations make up nearly all of UL Solutions' total revenue and are composed of two segments: industrial and consumer. UL Solutions' remaining business includes software and advisory, which complements its core TIC offerings. The firm operates globally.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.